681 related articles for article (PubMed ID: 24378529)
1. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations.
de Lédinghen V; Vergniol J; Capdepont M; Chermak F; Hiriart JB; Cassinotto C; Merrouche W; Foucher J; Brigitte le B
J Hepatol; 2014 May; 60(5):1026-31. PubMed ID: 24378529
[TBL] [Abstract][Full Text] [Related]
2. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
[TBL] [Abstract][Full Text] [Related]
3. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography.
Yilmaz Y; Ergelen R; Akin H; Imeryuz N
Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1330-4. PubMed ID: 23660937
[TBL] [Abstract][Full Text] [Related]
6. MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY.
Paul J; Venugopal RV; Peter L; Shetty KNK; Shetti MP
Arq Gastroenterol; 2018; 55(1):7-13. PubMed ID: 29561981
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
8. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound.
Carvalhana S; Leitão J; Alves AC; Bourbon M; Cortez-Pinto H
Liver Int; 2014 Jul; 34(6):e111-7. PubMed ID: 24034415
[TBL] [Abstract][Full Text] [Related]
9. Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.
Thiele M; Rausch V; Fluhr G; Kjærgaard M; Piecha F; Mueller J; Straub BK; Lupșor-Platon M; De-Ledinghen V; Seitz HK; Detlefsen S; Madsen B; Krag A; Mueller S
J Hepatol; 2018 May; 68(5):1025-1032. PubMed ID: 29343427
[TBL] [Abstract][Full Text] [Related]
10. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
Chan WK; Nik Mustapha NR; Mahadeva S
J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
[TBL] [Abstract][Full Text] [Related]
11. Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan
de Lédinghen V; Hiriart JB; Vergniol J; Merrouche W; Bedossa P; Paradis V
Dig Dis Sci; 2017 Sep; 62(9):2569-2577. PubMed ID: 28577247
[TBL] [Abstract][Full Text] [Related]
12. Genetic Variants in nicotinamide-N-methyltransferase (NNMT) gene are related to the stage of non-alcoholic fatty liver disease diagnosed by controlled attenuation parameter (CAP)-fibroscan.
Hasan EM; Abd Al Aziz RA; Sabry D; Darweesh SK; Badary HA; Elsharkawy A; Abouelkhair MM; Yosry A
J Gastrointestin Liver Dis; 2018 Sep; 27(3):265-272. PubMed ID: 30240470
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of controlled attenuation parameter measured by transient elastography for the non-invasive assessment of liver steatosis: a prospective study.
Lupșor-Platon M; Feier D; Stefănescu H; Tamas A; Botan E; Sparchez Z; Maniu A; Badea R
J Gastrointestin Liver Dis; 2015 Mar; 24(1):35-42. PubMed ID: 25822432
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan
Oeda S; Takahashi H; Imajo K; Seko Y; Ogawa Y; Moriguchi M; Yoneda M; Anzai K; Aishima S; Kage M; Itoh Y; Nakajima A; Eguchi Y
J Gastroenterol; 2020 Apr; 55(4):428-440. PubMed ID: 31654131
[TBL] [Abstract][Full Text] [Related]
15. Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.
Karlas T; Berger J; Garnov N; Lindner F; Busse H; Linder N; Schaudinn A; Relke B; Chakaroun R; Tröltzsch M; Wiegand J; Keim V
World J Gastroenterol; 2015 Apr; 21(16):4894-902. PubMed ID: 25945002
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP).
Cardoso AC; Perez RM; de Figueiredo-Mendes C; Carvalho Leite N; Moraes-Coelho HS; Villela-Nogueira CA
J Viral Hepat; 2018 Nov; 25(11):1244-1250. PubMed ID: 29768686
[TBL] [Abstract][Full Text] [Related]
17. Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?
Mikolasevic I; Orlic L; Franjic N; Hauser G; Stimac D; Milic S
World J Gastroenterol; 2016 Aug; 22(32):7236-51. PubMed ID: 27621571
[TBL] [Abstract][Full Text] [Related]
18. Correlation of the controlled attenuation parameter with indices of liver steatosis in overweight or obese individuals: a pilot study.
Ferraioli G; Tinelli C; Lissandrin R; Zicchetti M; Faliva M; Perna S; Perani G; Alessandrino F; Calliada F; Rondanelli M; Filice C;
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):305-12. PubMed ID: 25629575
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China.
Yu XY; Song XX; Tong YL; Wu LY; Song ZY
Medicine (Baltimore); 2020 Nov; 99(48):e23360. PubMed ID: 33235107
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of controlled attenuation parameter in a health check-up cohort.
Kwak MS; Chung GE; Yang JI; Yim JY; Chung SJ; Jung SY; Kim JS
Liver Int; 2018 May; 38(5):915-923. PubMed ID: 28940824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
